- Home
- PVL vs CELU Comparison
PVL vs CELU Comparison
Compare PVL & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PVL | CELU |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 56.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PVL | CELU |
|---|---|---|
| Price | $1.89 | $1.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 81.6K | 65.2K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 19.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | $3,511,891.00 | ★ $40,578,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | $29.20 | ★ N/A |
| Revenue Growth | ★ 11.77 | N/A |
| 52 Week Low | $1.30 | $1.00 |
| 52 Week High | $2.04 | $4.35 |
Technical Indicators
Market Signals| Indicator | PVL | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 55.41 |
| Support Level | $1.82 | $1.62 |
| Resistance Level | $1.83 | $2.18 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 86.67 | 60.76 |
Price Performance
Historical ComparisonAbout PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.